GrantSet

Grant opportunity · PAR-25-074

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Applications close76 days leftOct 14, 2026
AgencyNational Institutes of Health
CategoryDiscretionary
Assistance listing93.394
OpensOct 15, 2024
ClosesOct 14, 2026
Award floor
Award ceiling
Expected awardsNot stated

Who can apply (as listed)

  • Native American tribal organizations (other than federally recognized governments)
  • Small businesses
  • Native American tribal governments (federally recognized)
  • Nonprofits without 501(c)(3) status (other than institutions of higher education)
  • State governments
  • Public and state-controlled institutions of higher education
  • Nonprofits with 501(c)(3) status (other than institutions of higher education)
  • Private institutions of higher education
  • Others (see the opportunity text)
  • City or township governments
  • Independent school districts
  • Special district governments
  • Public housing authorities / Indian housing authorities
  • County governments
  • For-profit organizations (other than small businesses)
From the listing

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, inc…

Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.

GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.